Q-Gen Cell Therapeutics
Q-Gen is Australia's leading and most innovative cell therapy contract manufacturer.
Our services
As one of the largest cell manufacturers in Australia we leverage our extensive expertise and state-of-the-art technologies to deliver high-quality products. Our team of highly skilled professionals work tirelessly to deliver exceptional customer service and technical support, ensuring that our clients receive tailored solutions that meet their unique requirements.
With specialist teams in manufacturing, quality control, quality assurance, supply chain, equipment engineering and regulatory compliance we can assist in all aspects of your clinical trial project. Our dedicated project management support and an unwavering commitment to cell therapy development ensures Q-Gen is your preferred manufacturing partner.
Our Facility
With 12 Grade B/ISO 7 cleanrooms scheduling with speed and the ability to manufacture concurrent batches can accelerate your clinical program
3 segragated Grade D, open layout cleanrooms allow comprehensive process development areas as well as closed system operations with reduced overheads
The Q-Gen facility has been at the forefront of the cell therapy manufacturing field for 25 years. From pre-clinical through to Phase III, the Q-Gen team has the experience to support and accelerate your project to success.
Photos from our lab
Why Manufacture in Brisbane?
The most northern capital of the eastern states of Australia provides a perfect platform to access the Asia/Pacific region. Close proximity to Brisbane International Airport, providing access to 24 hour freight flights with direct routes to 32 international and 62 domestic destinations reducing lead times to and from the clinic.
Along with the interconnected hospital precincts, advanced medical infrastructure and mild seasonal weather conditions, Brisbane is the ideal location for cell therapy manufacture to access the Asia/Pacific region. In addition to time zone and cultural advantages, strong and long trade and investment relationships have been fostered with countries in Asia.
The Australian government supports our thriving regenerative medicine and cell therapy research sector by providing the Research and Development (R&D) tax incentive allowing for a refundable tax offset equal to the entity’s company tax rate plus an 18.5% premium for eligible entities with an aggregated turnover of less than $20 million per annum. Australia has a strong basic and translational research eco-system and a thriving regenerative medicine industry sector. Our clinical trials eco-system allows for the rapid recruitment of patients and includes impressive speed to market for Phase 1 clinical trials.